Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation

Masahiro Shinoda, Hirotoshi Ebinuma, Osamu Itano, Yoshiyuki Yamagishi, Hideaki Obara, Minoru Kitago, Nobuhiro Nakamoto, Taizo Hibi, Hiroshi Yagi, Yuta Abe, Kentaro Matsubara, Po sung Chu, Yuko Wakayama, Nobuhito Taniki, Akihiro Yamaguchi, Ryusuke Amemiya, Rei Miyake, Takamasa Mizota, Takanori Kanai, Yuko Kitagawa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aim: Simeprevir (SMV) is a protease inhibitor which demonstrates good tolerability and high antiviral response in patients with hepatitis C. The clinical outcomes of triple therapy using simeprevir, pegylated interferon and ribavirin (SMV/PEG IFN/RBV) for recurrent hepatitis C after living donor liver transplantation (LDLT) have not been well reported. In this study, we assessed the outcomes of patients with recurrent hepatitis C (genotype 1) after LDLT who received triple therapy at our hospital. Methods: SMV/PEG IFN/RBV was administrated for 12 weeks (triple therapy), followed by another 12 weeks or extended period of PEG IFN/RBV (dual therapy). Virological response, interaction with calcineurin inhibitors and adverse events were retrospectively analyzed. Results: Ten patients with recurrent hepatitis C after LDLT completed 12 weeks of triple therapy. Nine patients achieved rapid or early virological response, and one patient was a non-responder. The nine responders received subsequent dual therapy, and the duration of dual therapy was extended (24 to 36 weeks) in five cases. Although one patient was in relapse 8 weeks after completing the standard duration (12 weeks) of dual therapy, eight patients achieved sustained virological response for 12 weeks (SVR12). The SVR12 rate was 80%. Trough levels of calcineurin inhibitor did not show marked changes after introduction of SMV in all cases. There were no major adverse events associated with SMV. Conclusion: SMV treatment may be a safe and effective option for recurrent hepatitis C after LDLT.

Original languageEnglish
Pages (from-to)1118-1128
Number of pages11
JournalHepatology Research
Volume46
Issue number11
DOIs
Publication statusPublished - 2016 Oct 1

Keywords

  • calcineurin inhibitor
  • direct-acting antiviral agent
  • living donor liver transplantation
  • recurrent hepatitis C
  • simeprevir
  • virological response

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation'. Together they form a unique fingerprint.

  • Cite this